Oncopeptides AB (publ) (ONCO.ST)
SEK 1.6
(6.83%)
SEK 1.6
(6.83%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 289.74 Million SEK | -17.41% |
| 2022 | 357.69 Million SEK | -75.93% |
| 2021 | 1.48 Billion SEK | -6.61% |
| 2020 | 1.59 Billion SEK | 115.21% |
| 2019 | 739.39 Million SEK | 76.34% |
| 2018 | 419.3 Million SEK | 69.33% |
| 2017 | 247.61 Million SEK | 116.3% |
| 2016 | 114.48 Million SEK | 114.59% |
| 2015 | 53.34 Million SEK | 61.13% |
| 2014 | 33.1 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 73.9 Million SEK | -11.7% |
| 2024 Q2 | 80.47 Million SEK | 8.87% |
| 2023 Q2 | 88.35 Million SEK | 19.64% |
| 2023 FY | 295.42 Million SEK | -17.41% |
| 2023 Q4 | 83.7 Million SEK | 99.3% |
| 2023 Q3 | 41.99 Million SEK | -52.47% |
| 2023 Q1 | 73.85 Million SEK | -26.95% |
| 2022 Q1 | 98.86 Million SEK | -71.73% |
| 2022 FY | 357.69 Million SEK | -75.93% |
| 2022 Q2 | 69.84 Million SEK | -29.36% |
| 2022 Q4 | 101.1 Million SEK | 13.79% |
| 2022 Q3 | 88.85 Million SEK | 27.22% |
| 2021 Q2 | 408.38 Million SEK | 11.47% |
| 2021 Q1 | 366.35 Million SEK | -28.39% |
| 2021 FY | 1.48 Billion SEK | -6.61% |
| 2021 Q3 | 361.59 Million SEK | -11.46% |
| 2021 Q4 | 349.74 Million SEK | -3.28% |
| 2020 Q2 | 399.33 Million SEK | 34.51% |
| 2020 FY | 1.59 Billion SEK | 115.21% |
| 2020 Q4 | 511.57 Million SEK | 33.4% |
| 2020 Q1 | 296.87 Million SEK | 21.55% |
| 2020 Q3 | 383.49 Million SEK | -3.97% |
| 2019 Q4 | 244.24 Million SEK | 28.82% |
| 2019 Q3 | 189.59 Million SEK | 10.4% |
| 2019 Q2 | 171.73 Million SEK | 40.85% |
| 2019 Q1 | 121.93 Million SEK | 9.64% |
| 2019 FY | 739.39 Million SEK | 76.34% |
| 2018 FY | 419.3 Million SEK | 69.33% |
| 2018 Q4 | 111.21 Million SEK | 7.99% |
| 2018 Q3 | 102.98 Million SEK | -28.02% |
| 2018 Q1 | 68.45 Million SEK | 2.62% |
| 2018 Q2 | 143.07 Million SEK | 109.02% |
| 2017 Q3 | 51.57 Million SEK | -23.32% |
| 2017 FY | 247.61 Million SEK | 116.3% |
| 2017 Q4 | 66.7 Million SEK | 29.34% |
| 2017 Q2 | 67.26 Million SEK | 8.34% |
| 2017 Q1 | 62.08 Million SEK | 21.52% |
| 2016 Q4 | 51.08 Million SEK | 107.11% |
| 2016 FY | 114.48 Million SEK | 114.59% |
| 2016 Q3 | 24.66 Million SEK | 5.04% |
| 2016 Q2 | 23.48 Million SEK | 54.05% |
| 2016 Q1 | 15.24 Million SEK | 0.0% |
| 2015 FY | 53.34 Million SEK | 61.13% |
| 2014 FY | 33.1 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NextCell Pharma AB | -576.01 Thousand SEK | 50401.466% |
| Biovica International AB (publ) | 133.72 Million SEK | -116.678% |
| Abliva AB (publ) | 27.86 Million SEK | -939.783% |
| Active Biotech AB (publ) | 44.8 Million SEK | -546.625% |
| Aptahem AB (publ) | 10.01 Million SEK | -2793.714% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 5.648% |
| BioInvent International AB (publ) | 441.4 Million SEK | 34.358% |
| BioArctic AB (publ) | 89.62 Million SEK | -223.28% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -248.382% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 80.865% |
| Cantargia AB (publ) | 290.01 Million SEK | 0.093% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1223.343% |
| CombiGene AB (publ) | 44.14 Million SEK | -556.364% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -49.74% |
| Fluicell AB (publ) | 28.61 Million SEK | -912.496% |
| Genovis AB (publ.) | 88.19 Million SEK | -228.521% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 66.287% |
| Mendus AB (publ) | 129.13 Million SEK | -124.371% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -5149.973% |
| LIDDS AB (publ) | 27.75 Million SEK | -944.054% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1538.557% |
| Saniona AB (publ) | 1.07 Million SEK | -26803.064% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1364.103% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -579.644% |
| Xintela AB (publ) | 57.31 Million SEK | -405.524% |
| Amniotics AB (publ) | 29.07 Million SEK | -896.65% |
| Corline Biomedical AB | 30.16 Million SEK | -860.442% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -922.885% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -115.114% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -399.295% |
| Intervacc AB (publ) | 79.78 Million SEK | -263.158% |
| Kancera AB (publ) | 63.07 Million SEK | -359.353% |
| Lipum AB (publ) | 37.3 Million SEK | -676.653% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -3894.293% |
| Nanologica AB (publ) | 69.88 Million SEK | -314.592% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 9.879% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 18.98% |
| AcouSort AB (publ) | 25.87 Million SEK | -1019.748% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -102.638% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -164.928% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -113.186% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1666.636% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -59.434% |
| Simris Alg AB (publ) | 38.64 Million SEK | -649.821% |
| Ziccum AB (publ) | 27.87 Million SEK | -939.336% |
| SynAct Pharma AB | 224.49 Million SEK | -29.065% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1721.729% |
| Camurus AB (publ) | 1.05 Billion SEK | 72.657% |
| 2cureX AB (publ) | 36.51 Million SEK | -693.433% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1877.384% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -3886.599% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1109.58% |
| I-Tech AB | 40.14 Million SEK | -621.695% |
| Cyxone AB (publ) | 28.21 Million SEK | -926.958% |
| Biosergen AB | 26.8 Million SEK | -980.779% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -555.89% |
| Alzinova AB (publ) | 36.39 Million SEK | -696.093% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -151.793% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -3588.087% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -161.235% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1871.061% |